Occurrence of a Clonal T-Cell Population in a Case of Chronic Myelomonocytic Leukemia

Anupama Patil1, Balasaheb Wanve2, Pradeep Kar1 and Shanthi Velusamy1

1Department of Pathology, SRL Diagnostics, Fortis Hospital, Bengaluru, Karnataka, India.
2Department of Hemato-Oncology, Fortis Hospital, Bengaluru, Karnataka, India.

ABSTRACT: Chronic myelo-monocytic leukemia (CMML) is an aggressive myeloid neoplasm with some features of a myelodysplastic syndrome (MDS) and others of a myeloproliferative neoplasm (MPN). Rarely, patients with CMML have a co-existing lympho-proliferative disorder (LPD). In most cases, the lymphoid neoplasm is diagnosed first, and the CMML is considered to be a secondary therapy-induced form of leukemia. We report herein a unique case of de-novo CMML, with an underlying clonal T-cell population and describe its clinical presentation and laboratory findings. A 70-year old male presented with a 3-month history of cough, dyspnea, abdominal distension and low-grade fever. Physical and radiological examination revealed hepatosplenomegaly but no lymphadenopathy. Peripheral blood had absolute monocytosis with marrow showing CMML with 10% blasts along with dysplasia in myeloid and erythroid lineages. Flow cytometry indicated possibility of chronic myelomonocytic leukemia with 13% monocytes along with an additional clonal population of gamma/delta T cells (15%) with aberrant immunophenotype. Polymerase chain reaction (PCR) analysis was positive for clonal T-cell rearrangement. A diagnosis of CMML with an underlying clonal T-CLPD was made. The synchronous occurrence of CMML and T-cell neoplasm may be attributed to a genetic mutation common to both. Currently, there are no treatment guidelines for group of patients; hence individualized therapeutic strategies should be implemented to enable symptomatic improvement and provide optimum care.

KEYWORDS: chronic myelomonocytic leukemia, T-cell leukemia, myelodysplastic syndromes, multiparametric flow cytometry

Received: April 30, 2020. Accepted: January 8, 2021.

Type: Case Report

Funding: The author(s) received no financial support for the research, authorship, and/or publication of this article.

Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Corresponding Author: Anupama Patil, Department of Pathology, SRL Diagnostics, Fortis Hospital, 154/9, Opp IIM-B, Bannerghatta Road, Bengaluru, Karnataka 560076, India. Email: itsagp@gmail.com

Introduction

Chronic myelo-monocytic leukemia (CMML) is an aggressive myeloid neoplasm with some features of a myelodysplastic syndrome (MDS) and others of a myeloproliferative neoplasm (MPN). According to 2016 iteration of the WHO Classification of hematopoietic neoplasms, a diagnosis of CMML requires the following criteria: (i) the presence of persistent peripheral blood monocytosis (monocyte count ≥1 × 10^9/L); (ii) Negative for BCR-ABL1 fusion gene; (iii) No rearrangement of PDGFRα, PDGFRβ, and FGFR1; (iv) Blasts constituting ≤20% of differential in peripheral blood and bone marrow; (v) Dysplasia involving 1 or more myeloid lineages.

Owing to its heterogeneous clinical presentation and overlapping clinico-pathological features with MDS, diagnosis of CMML can be a challenging process. Very rarely, patients with CMML have a co-existing lympho-proliferative disorder (LPD). In most cases, the lymphoid neoplasm is diagnosed first, and the CMML is considered to be a secondary therapy-induced form of leukemia. We report herein a unique case of de-novo CMML, with an underlying clonal T-cell population and describe its clinical presentation and laboratory findings.

Case Summary

A 70-year old male presented with a 3-month history of cough, dyspnea, abdominal distension and low-grade fever. There was no history of prior exposure to ionizing radiation or cytotoxic agents; nor any family history of leukemia. Physical examination revealed abdominal distension with palpable splenomegaly 5 cm below costal margin and mild hepatomegaly, but no palpable lymphadenopathy. On admission, complete blood count showed hemoglobin (Hb) 10.1 g/dL, red blood cell (RBC) 3.36 million/µL, hematocrit (Hct) 32.2%, platelets (PLT) 35 × 10^9/µL, white blood cells (WBC) 26.3 × 10^3/µL with 65% neutrophils, 11% lymphocytes (2.89 × 10^9/µL), and 24% monocytes (6.3 × 10^9/µL). Marrow aspirate smear showed medium to large blast cells (10%), having scanty agranular cytoplasm and nuclei showing fine chromatin. In addition, increased number of mature monocytoid cells (12%) was present and 5% lymphoid cells were noted. Myeloid and erythroid series showed dyspoietic changes. Bone marrow trephine biopsy examination revealed normocellular marrow spaces with infiltration of few histiocytic cells having vesicular chromatin and abundant cytoplasm. Immunohistochemistry (IHC) performed on trephine biopsy block with CD68 highlighting monocytic-macrophage lineage cells (25%) and CD56 positivity in around 10% of the cells. CD34 was negative.

Flow cytometry performed on the bone marrow sample indicated possibility of chronic myelo-monocytic leukemia with 13% cells showing phenotypic features of monocytes (positive for CD4, CD16, CD13, CD3, HLADR, CD64, and CD36; 43% of gated monocytes showed CD16 expression). In addition, a population of gamma/delta T cells (15%) was noted with aberrant immunophenotype (CD3+, CD7+, CD5-,
CD4−, CD8−, dim CD16+, and CD56+), positive for TCR-gamma/delta and negative for TCR-alpha/beta. Chromosome analysis revealed an apparently normal male karyotype in all the metaphases analyzed with no structural or numerical abnormalities. Cytogenetic study for deletion of 7q31 locus was negative. Mutation panel for MPNs was negative (BCR/ABL, JAK2V617F, JAK2 EXON12, CALR, and MPL). Polymerase chain reaction (PCR) analysis was positive for clonal T-cell rearrangement. An extensive work-up including bacterial/fungal cultures, viral serology, and autoimmune panels ruled out secondary causes. Further, the possibility of hepatosplenic T-cell lymphoma (HSTL) was considered as a differential, but the characteristic intrasinusoidal distribution of neoplastic cells seen in HSTL was not evident on the bone marrow trephine biopsy sections. Likewise, T-cell large granular lymphocytic leukemia (T-LGLL) was yet another consideration. But the lymphocytes morphology on peripheral smear was found to be unremarkable. Further work-up for accurate classification of the clonal T-cell population was not possible owing to the deteriorating clinical condition of the patient. Hence, in correlation with clinico-pathological, flow cytometric, and molecular findings, a diagnosis of CMML with an underlying clonal T-cell lympho-proliferative disorder (T-CLPD) was made. The patient was started on hydroxyurea; however, within 10 days of presentation, patient passed away due to pulmonary complications.

We hereby certify that all appropriate written consent forms were obtained from patient. Case reports or case series do not require ethics approval at our institution.

**Discussion**

The combination of CMML and lymphoma is rare. However, a polyclonal hypergammaglobulinemia is commonly recorded, possibly indicative of the elevated levels of inflammatory cytokines. Although few studies have reported concurrent MDS and clonal T-cell proliferations, there is a paucity of data on the association of CMML (MDS/MPN) with T-CLPD. To our knowledge, there have been only 4 such cases reported in the literature. In most patients of CMML with a co-existing LPD, the lymphoid neoplasm is detected first and the CMML is considered to be a secondary therapy-induced form of leukemia; in others, CMML is first diagnosed and later, a lymphoid neoplasm is detected during follow up. But, in some patients, similar to our patient, both malignancies are recognized simultaneously and there is no history of exposure to carcinogenic agents.

The underlying pathogenic mechanism of multiple hemtolymphoid neoplasms occurring together is not clear. A plausible theory is the instability of a common precursor stem cell or a precursor cells of lymphocytes and monocytes. Recent studies have described cases with clonal hematopoiesis-type mutations as factors of common origin of lymphoid and myeloid.
Other evidence has suggested that immune dysregulation induced by expanded cytotoxic T-cell clones may result in immune dysregulation, which ultimately manifests as intrinsic stem cell defect causing suppression of normal hematopoiesis, characteristic of MDS/MPN type disorders. Further, it is interesting to note that loss of TET2 can be detected in both myeloid and lymphoid malignancies and TET2 inactivating mutations are the most frequently detected somatic mutations in CMML, indicative of a mutation occurring in a hematopoietic progenitor cell and the tumor suppressor nature of TET2 in both these malignancies. Additional genetic studies on this mutation may aid in identifying a potential diagnostic bio-marker or a theranostic target. Currently, there are no treatment guidelines for this group of patients; hence, individualized therapeutic strategies should be implemented to enable symptomatic improvement and provide optimum care.

**Conclusion**

This rare case demonstrates the possibility of developing concurrent T-CLPDs and CMML in the same patient and physicians managing patients with MDS/MPN should be aware of this possibility. A detailed diagnostic workup should be conducted efficiently to initiate supportive therapy expeditiously. Currently, there are no treatment guidelines and further large scale studies are needed to formulate standard management guidelines for this group of patients. As of now, for these patients, individualized therapeutic strategies should be implemented to enable symptomatic improvement and provide optimum care. (Figure 1 and 2).

**ORCID iD**

Anupama Patil  https://orcid.org/0000-0002-9611-1869

**REFERENCES**

1. Itzykson R, Duchmann M, Lucas N, Solary E. CMML: clinical and molecular aspects. *Int J Hematol*. 2017;105:711-719. http://link.springer.com/10.1007/s12185-017-2243-z
2. Patnaik MM, Parikh SA, Hanson CA, Tefferi A. Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review. *Br J Haematol*. 2014;165:273-286.
3. Orazi A, Bennett JM, Germing J, Bruning R, Bain B, Cazzola M. WHO classification of tumours of haematopoietic and lymphoid tissues. In: Swerdlow S, Campo E, Harris N, Jaffe E, Pileri S, Stein H, et al, eds. IARC Press; 2017:82-86.

---

**Figure 2.** Flow cytometric immunophenotyping showing 2 sub-populations (monocytes which are CD64+, CD36+, T-cells which are CD3+, CD7+, CD56+, and TCR-gamma/delta+).
4. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood*. 2016;127:2394-2405.

5. Provan AB, Major RV, Smith AG, Wilkins B, Hodges E, Smith JL. Chronic myelomonocytic leukaemia associated with T cell receptor delta gene rearrangement. *J Clin Pathol*. 1991;44:344-345.

6. Gaulier J, Jary-Bourgugniart L, Serne R, Pulik M, Davi F, Raphael M. Occurrence of angioimmunoblastic T cell lymphoma in a patient with chronic myelomonocytic leukaemia features. *Leuk Lymphoma*. 2001;40:197-204. http://www.ncbi.nlm.nih.gov/pubmed/11426612.

7. Robak T, Urbanska-Ryli H, Smudowski P, et al. Chronic myelomonocytic leukaemia coexisting with B-cell chronic lymphocytic leukemia. *Leuk Lymphoma*. 2003;44:2001-2008.

8. Song S. A case report: concurrent chronic myelomonocytic leukemia and T-cell large granular lymphocytic leukaemia. *Leuk Lymphoma*. 2015;15:110-114.

9. Hagihara M, Inoue M, Kodama K, Uchida T, Hua J. Simultaneous manifesta-tion of chronic myelomonocytic leukemia and multiple myeloma during treat-ment. *Leuk Lymphoma*. 2003;44:1246-1254. https://pubmed.ncbi.nlm.nih.gov/2593715/

10. Soriano PK, Stone T, Baqai J, Sana S. A case of synchronous bone marrow chronic myelomonocytic leukemia and multiple myeloma. *Br J Haematol*. 2015;172:637-642.

11. Ueki K, Sato S, Tamura J, et al. Three cases of multiple myeloma developing into chronic myelomonocytic leukemia: natural history and prognostic determinants. *Exp Hematol*. 2009;37:947-955.

12. Provan AB, Majer RV, Smith AG, Wilkins B, Hodges E, Smith JL. Chronic myelomonocytic leukaemia. *Clin Exp Dermatol*. 2001;26:427-432.

13. Pemmaraju N, Shah D, Kantarjian H, et al. Characteristics and outcomes of chronic myelomonocytic leukaemia. *Br J Haematol*. 2013;162:661-668.

14. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood*. 2016;127:2394-2405.

15. Koides PA, Bennett JM. Transformation of chronic myelomonocytic leukemia to acute lymphoblastic leukemia: case report and review of the literature of lympho-blastic transformation of myelodysplastic syndrome. *Ann J Hematol*. 1995;49:157-162.

16. Saillard C, Guermouche H, Derrieux C, et al. Response to 5-azacytidine in a patient with chronic myelomonocytic leukemia. *Cancer*. 2009;115:2560-2567.

17. Tefferi A, Hoagland H, Therneau T, Pierre V. Chronic myelomonocytic leukemia. *N Engl J Med*. 2012;367:87-98.

18. Solal-Céligny P, Desaint B, Herrera A, et al. Chronic Myelomonocytic Leuke-mia According to FAB Classification: analysis of 35 Cases. *Blood*. 1984;63:634-638. https://pubmed.ncbi.nlm.nih.gov/6582893/

19. Kouides PA, Bennett JM. Transformation of chronic myelomonocytic leukemia to acute lymphoblastic leukemia: case report and review of the literature of lymphoblastic transformation of myelodysplastic syndrome. *Ann J Hematol*. 1995;49:157-162.

20. Yamamoto M, Nakagawa M, Ichimura N, et al. Lymphoblastic transformation of chronic myelomonocytic leukemia in an infant. *Am J Hematol*. 1996;52:212-214.

21. Baumann M, Liboch M, Hansen R, Heckman M, Hanson G. Concurrent myelodysplasia and lymphoproliferation: a disorder of the true pluripotent stem cell? *Q J Med*. 1985;59:199-211. https://pubmed.ncbi.nlm.nih.gov/4023169/

22. Wong AK, Bunce CM, Lord JM, Sahl J, Brown G. Evidence that precursor cells of monocytes and B-lymphocytes are closely related. *Exp Hematol*. 1989;17:968-973. http://www.ncbi.nlm.nih.gov/pubmed/2789147.

23. Lewis NE, Petrova-Drus K, Huet S, et al. Clonal hematopoiesis in angioimmu-noblastic T-cell lymphoma with divergent evolution to myeloid neoplasms. *Blood Adv*. 2020;4:2261-2271. https://pubmed.ncbi.nlm.nih.gov/32442302/

24. Tiacci E, Venanzi A, Avanzi S, et al. High-risk clonal hematopoiesis as the ori-gen of AITL and NPM1-mutated AML. *Nat Engl J Med*. 2018;379:981-984. https://pubmed.ncbi.nlm.nih.gov/30188450/

25. Risitanø AM, Maciejewski JP, Selleri C, Rotoli B. Function and malfunction of hematopoietic stem cells in primary bone marrow failure syndromes. *Curr Stem Cell Res Ther*. 2007;2:29-52.

26. Forza C, Contini S, Gallesu A, et al. Patients with myelodysplastic syndromes display several T-cell expansions, which are mostly polyclonal in the CD4+ subset and oligoclonal in the CD8+ subset. *Exp Hematol*. 2009;37:947-955.

27. Matsutani T, Yoshioka T, Tsuruta Y, et al. Determination of T-cell receptors of clonal CD8-positive T-cells in myelodysplastic syndrome with erythroid hypoplasia. *Leuk Res*. 2003;27:305-312. https://linkinghub.elsevier.com/retrieve/pii/S014521260200173X.

28. Epperson DE, Nakamura R, Saundhararajah Y, Melenhorst J, Barrett AJ. Oligo-clonal T-cell expansion in myelodysplastic syndrome: evidence for an autoim-mune process. *Leuk Res*. 2001;25:1075-1083.

29. Quivoron C, Couronné L, Della Valle V, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. *Cancer Cell*. 2011;20:25-38.

30. Malcovati L, Papaemmanuil E, Ambaglio I, et al. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. *Blood*. 2014;124:1513-1521.

31. Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management. *Am J Hematol*. 2018;93:184-190.

32. Patel BJ, Przychoden B, Thota S, et al. Genomic determinants of chronic myelomonocytic leukemia. *Leukemia*. 2017;31:2815-2823.